LLY — Eli Lilly and Company

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabe… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1064.74
Market Cap$928.88B
Float889.3M
Shares Outstanding891.7M
P/E (Forward)28.09
P/E (TTM)37.04
Price/Sales (TTM)12.86
vs. Analyst Target+13.6% to analyst PT
Profit Margin34.99%
Operating Margin (TTM)49.39%
Revenue (TTM)$72.25B
Earnings Growth (YoY)169.90%
Dividend Rate6.9%
Analyst Target Price$1210.00 (29 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $24.54B $6.19B $19.06B $8.91B
2021 $28.32B $5.58B $21.01B $8.04B
2022 $28.54B $6.24B $21.91B $8.66B
2023 $34.12B $5.24B $27.04B $8.57B
2024 $45.04B $10.59B $36.62B $15.23B
2025 $65.18B $20.64B $54.62B $27.94B

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $15.56B $5.66B
Sep 2025 $17.60B $5.58B
Dec 2025 $19.29B $6.64B
Mar 2026 $19.80B $7.40B

Ownership & Float

Insider Ownership0.2%
Institutional Ownership85.4%
Short Float0.9%
% of All Funds Holding49.77%
Number of Funds Holding4,091

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$961.07Near-term / short-term trend
Weekly40-Week SMA$951.61Medium-term trend
Weekly80-Week SMA$869.84Cyclical trend (business cycle)
Weekly200-Week SMA$693.36Secular trend (multi-year)
Monthly10-Month SMA$951.68Near-term monthly trend
Monthly20-Month SMA$881.39Medium-term monthly trend
Monthly40-Month SMA$754.62Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$867.00 support 1.02x 5 months ago

Historical Earnings Reactions (121 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.07% 0.00% 47.93% 4.75% -4.63%
1 Day 0.04% -0.08% 49.59% 7.11% -11.47%
1 Week 0.52% 0.17% 52.89% 12.65% -9.15%
2 Weeks 1.26% 0.76% 52.89% 21.41% -14.99%
1 Month 0.78% -0.08% 49.17% 22.39% -24.94%

Next earnings: July 19, 2026 (53 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan0.9%52.0%50
Feb-0.2%50.0%50
Mar1.2%60.8%51
Apr1.8%56.9%51
May0.9%38.0%50
Jun2.4%64.0%50
Jul0.0%54.0%50
Aug0.5%42.0%50
Sep0.0%46.0%50
Oct1.2%56.0%50
Nov2.8%74.0%50
Dec3.0%58.0%50

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.06% 49.7% 2384
Tuesday 0.08% 47.9% 2586
Wednesday 0.09% 50.4% 2587
Thursday 0.03% 49.6% 2537
Friday 0.03% 49.2% 2524

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 85.4%

Insider Transactions — Smart Summary

Total insider ownership: 0.2%

12-Month Insider Activity Summary

Total Filings44
Net Value-$416,947.502
Net Shares Change-4,133,091
% of Float-0.5%
C-Suite Filings8
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
LILLY ENDOWMENT INC -$338M 2 2 sell
Ricks David A President, Chair, and CEO +$1.1M 1 1 buy
Fyrwald J Erik +$1.0M 1 1 buy
Van Naarden Jacob EVP and Pres., Lilly Oncology +$647,360 1 1 buy
Skovronsky Daniel EVP, CSO and Pres. LRL and LLY Imm +$634,405 1 1 buy
Alvarez Ralph +$500,472.532 1 1 buy
Montarce Lucas EVP and CFO +$494,626.99 1 1 buy
JACKSON JAMERE +$127,912.6 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-08-12 – 2025-08-15 8 8 +$3.6M 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-07 LILLY ENDOWMENT INC -$15.8M Transaction at $995.36, now +7.0%
2025-08-13 Van Naarden Jacob EVP and Pres., Lilly Oncology +$647,360 Transaction at $647.36, now +64.5%
2025-08-12 Ricks David A President, Chair, and CEO +$1.1M Transaction at $644.77, now +65.1%
2025-08-15 Montarce Lucas EVP and CFO +$494,626.99 Transaction at $691.79, now +53.9%
2025-08-12 Skovronsky Daniel EVP, CSO and Pres. LRL and LLY Imm +$634,405 Transaction at $634.40, now +67.8%
2025-08-12 Fyrwald J Erik +$1.0M Transaction at $642.33, now +65.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Eli Lilly and Company (LLY) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for LLY on Trend Edge →